Patients | n = 5 |
---|---|
Gender (F/M), n | 4/1 |
Age (years), mean ± SD | 64.0 ± 10.6 |
Disease duration (years), mean ± SD | 21.8 ± 10.9 |
Patients RF-positive, n (%) | 4 (80%) |
Patients ACPA-positive, n (%) | 5 (100%) |
Patients ANA-positive, n (%) | 4 (80%) |
Patients anti-dsDNA-positive, n (%) | 1 (20%) |
TCZ treatment duration (months), mean ± SD | 43.4 ± 32.4 |
Patients treated with prednisone (2.5–7.5 mg/day), n (%) | 4 (80%) |
Patients treated with methotrexate (7.5–15 mg/week), n (%) | 3 (60%) |
Patients treated with hydroxychloroquine (200–400 mg/day), n (%) | 2 (40%) |